Notice of Appeal
Molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] (previously part of ID4038 - Therapeutics for people with COVID-19)
This appeal hearing will hear appeals against the Final Draft Guidance for the above technologies by the following organisations:
- AstraZeneca
- Gilead Sciences
- Merck Sharp & Dohme
The appeal panel will convene on Tuesday 2 May and Wednesday 3 May 2023 at 10.00am via Zoom to hear oral representations from the appellants.
This page was last updated: